(Q53618240)

16 May 2018

title

Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. (English)

1 reference

16 May 2018

author

Carsten Denkert

7

1 reference

16 May 2018

Andreas Schneeweiss

13

object named as

Andreas Schneeweiss

1 reference

16 May 2018

21

Sibylle Loibl

1 reference

16 May 2018

18

Michael Untch

1 reference

16 May 2018

19

Patrick Neven

1 reference

16 May 2018

author name string

Caterina Fontanella

1

1 reference

16 May 2018

Bianca Lederer

2

1 reference

16 May 2018

Stephan Gade

3

1 reference

16 May 2018

Mieke Vanoppen

4

1 reference

16 May 2018

Jens Uwe Blohmer

5

1 reference

16 May 2018

Serban Dan Costa

6

1 reference

16 May 2018

Holger Eidtmann

8

1 reference

16 May 2018

Bernd Gerber

9

1 reference

16 May 2018

Claus Hanusch

10

1 reference

16 May 2018

Jörn Hilfrich

11

1 reference

16 May 2018

Jens Huober

12

1 reference

16 May 2018

Stefan Paepke

14

1 reference

16 May 2018

Christian Jackisch

15

1 reference

16 May 2018

Keyur Mehta

16

1 reference

16 May 2018

Valentina Nekljudova

17

1 reference

16 May 2018

Gunter von Minckwitz

20

1 reference

16 May 2018

language of work or name

English

0 references

publication date

13 February 2015

1 reference

16 May 2018

Breast Cancer Research and Treatment

published in

1 reference

16 May 2018

volume

150

1 reference

16 May 2018

issue

1

1 reference

16 May 2018

page(s)

127-139

1 reference

16 May 2018

https://scigraph.springernature.com/pub.10.1007/s10549-015-3287-5

exact match

0 references

cites work

Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Obesity and diabetes in the developing world--a growing challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Risk prediction for breast, endometrial, and ovarian cancer in white women aged 50 y or older: derivation and validation from population-based cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

The growing challenge of obesity and cancer: an inflammatory issue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Obesity, metabolic dysregulation, and cancer: a growing concern and an inflammatory (and microenvironmental) issue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Inflammation and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Obesity or overweight is associated with worse pathological response to neoadjuvant chemotherapy among Chinese women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Body mass index, diabetes, and triple-negative breast cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Selecting the neoadjuvant treatment by molecular subtype: how to maximize the benefit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Response-guided neoadjuvant chemotherapy for breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primar

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Minireview: Obesity and breast cancer: a tale of inflammation and dysregulated metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Treating breast cancer in the 21st century: emerging biological therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Effect of obesity on disease-free and overall survival in node-positive breast cancer patients in a large French population: a pooled analysis of two randomised trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3287-5

10.1007/S10549-015-3287-5

21 January 2018

Identifiers

DOI

1 reference

16 May 2018

1 reference

16 May 2018